SPDR S&P Telecom (XTL) 57.41 $XTL
XTL Biopharmaceuticals Provides Financial and Operational Update for the Second Quarter of 2014
PR Newswire - Tue Sep 02, 11:09AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three and six month periods ended June 30, 2014.
XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity
PR Newswire - Wed Jul 16, 8:18AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of Targeted Therapeutic Agents for Systemic Lupus Erythematosus. The article was written by Zev Sthoeger, Amir Sharabi and Edna Mozes. The article has been published in the Journal of Autoimmunity.
XTL Biopharmaceuticals Receives Correspondence Regarding Nasdaq Listing Requirements
PR Newswire - Thu Jun 12, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that it received a letter from the Nasdaq Stock Market LLC ("Nasdaq"

dated June 9, 2014 relating to the May 19, 2014 resignation of director Marc Allouche.
XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial
PR Newswire - Tue Mar 25, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1 compound for the treatment of Lupus (Systemic Lupus Erythematosus - SLE) patients.
The Comprehensive Guide to Telecom ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 10:47AM CST
Telecom industry is expected to maintain its upward momentum going forward.